secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001558370-22-013188
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024
--------------------------------------------------------------------------------

- Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.
- Positive Phase 1/2 data for botaretigene sparoparvovec (AAV-RPGR) shows vision improvements in XLRP; Phase 3 Lumeos enrolling.
- Secured up to $100M senior secured financing from Perceptive secured by manufacturing facilities; $75M received at close.
- Cash and equivalents $72.1M at June 30 plus $15.9M Janssen receivable; cash runway to Q4 2024.
- R&D expenses increased to $24.0M from $15.2M due to manufacturing and clinical costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/0001558370-22-013188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/mgtx-20220811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer